Steve Hoerter, Chief Commercial Officer at Agios Pharmaceuticals,
Inc., Elected to Board of Directors
WALTHAM, Mass.--(BUSINESS WIRE)--May 21, 2018--
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage
biopharmaceutical company focused on addressing key mechanisms of tumor
drug resistance, today announced that it has elected Mr. Steven L.
Hoerter, Chief Commercial Officer at Agios Pharmaceuticals, Inc., to its
Board of Directors, effective as of May 17, 2018. Mr. Hoerter will serve
as an independent director and a member of the Nominating and Corporate
Governance Committee. The number of Deciphera directors was increased
from eight to nine in connection with Mr. Hoerter’s election.
“We are delighted to welcome Steve to our Board of Directors, and we
value the expertise he brings to Deciphera at this strategically
important time in the evolution of the Company,” stated Michael D.
Taylor, Ph.D., President and Chief Executive Officer of Deciphera
Pharmaceuticals. “Mr. Hoerter’s extensive commercial experience will be
invaluable as we advance DCC-2618 through late stage development and
plan for the possible registration and launch of this potential
treatment for patients with gastrointestinal stromal tumors.”
“I’m excited by Deciphera’s robust oncology pipeline, and I look forward
to helping guide the outstanding team at Deciphera as they work to bring
these novel, precision medicines to patients,” said Mr. Hoerter.
Mr. Hoerter has served as Chief Commercial Officer of Agios since early
2016 where he built and leads the team responsible for the
commercialization of the company’s portfolio of first-in-class medicines
for oncology and rare genetic diseases. He has more than 25 years of
global pharmaceutical and biotechnology experience, having held senior
positions at leading oncology companies. Prior to joining Agios, Mr.
Hoerter was executive vice president and Chief Commercial Officer at
Clovis Oncology, Inc., where he built and led the company’s commercial
organization. Before joining Clovis, he was General Manager and
Management Center Head at Roche for the Sub-Saharan Africa and Indian
Ocean Region. From 2005 to 2010, Mr. Hoerter held a variety of positions
at Genentech, Inc., including serving on the senior leadership team for
Genentech’s BioOncology business. Prior to that, Mr. Hoerter held
commercial roles at Chiron Corporation and Eli Lilly and Company in the
U.S., Europe, and Africa. Mr. Hoerter was a member of the Board of
Directors of Ignyta, Inc., a biotechnology company focused on precision
medicine in oncology, until the company’s acquisition by Roche earlier
this year. Mr. Hoerter received his B.A. from Bucknell University,
M.B.A. from Tilburg University and M.S. in management from Purdue
University.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company
focused on improving the lives of cancer patients by tackling key
mechanisms of drug resistance that limit the rate and/or durability of
response to existing cancer therapies. Our small molecule drug
candidates are directed against an important family of enzymes called
kinases, known to be directly involved in the growth and spread of many
cancers. We use our deep understanding of kinase biology together with a
proprietary chemistry library to purposefully design compounds that
maintain kinases in a “switched off” or inactivated conformation. These
investigational therapies comprise tumor-targeted agents designed to
address therapeutic resistance causing mutations and immuno-targeted
agents designed to control the activation of immunokinases that suppress
critical immune system regulators, such as macrophages. We have used our
platform to develop a diverse pipeline of tumor-targeted and
immuno-targeted drug candidates designed to improve outcomes for
patients with cancer by improving the quality, rate and/or durability of
their responses to treatment.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180521005538/en/
Source: Deciphera Pharmaceuticals, Inc.
Media:
The Yates Network
Gina Nugent, 617-460-3579
gina@theyatesnetwork.com
or
Investor
Relations:
Argot Partners
Laura Perry or Sam Martin,
212-600-1902
Laura@argotpartners.com
or Sam@argotpartners.com
or
Company:
Deciphera
Pharmaceuticals, LLC
Christopher J. Morl, 781-209-6418
Chief
Business Officer
cmorl@deciphera.com
